Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry
You may also be interested in...
Is The Non-compete Clause For Cross-border Deals In India A Burden Or A Boost?
Deal makers are cautiously viewing the fallout of a recent government statute to prevent non-compete clauses in cross-border deals for existing Indian companies except in special circumstances. Experts await clarification on the statute but some say the new norm will impede deals and affect valuations.
Global Firms Can Now Buy A Controlling Stake In Indian Companies, But The Debate Is Not Over
A truce between government departments was reached on the issue of foreign direct investments in the pharmaceutical industry. In the new setting, the “non-compete” clause will be removed lending flexibility to the seller to start up a competing enterprise.
India Proposes Stricter Rules For Local Buy-Outs By Foreign Firms
A proposal by an Indian government department may make buy-outs of existing local drug units difficult for global companies. The new provisions include removal of a non-compete clause and several other pre-conditions for the buyer.